Design
Review
Authors
Loading...
Does not change cardiorenal syndrome management; leaves open the need for randomized subtype-specific trials.
Key points are not available for this paper at this time.
Manolis et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: